BioLine RX Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more
BioLine RX Ltd - Asset Resilience Ratio
BioLine RX Ltd (BLRX) has an Asset Resilience Ratio of 43.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how BioLine RX Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BioLine RX Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA17.30 Million | 43.46% |
| Total Liquid Assets | ILA17.30 Million | 43.46% |
Asset Resilience Insights
- Very High Liquidity: BioLine RX Ltd maintains exceptional liquid asset reserves at 43.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioLine RX Ltd Industry Peers by Asset Resilience Ratio
Compare BioLine RX Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for BioLine RX Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for BioLine RX Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.46% | ILA9.13 Million | ILA38.91 Million | -37.14pp |
| 2023-12-31 | 60.60% | ILA38.74 Million | ILA63.92 Million | +7.59pp |
| 2022-12-31 | 53.02% | ILA40.49 Million | ILA76.38 Million | -1.22pp |
| 2021-12-31 | 54.24% | ILA44.15 Million | ILA81.39 Million | +42.07pp |
| 2020-12-31 | 12.17% | ILA5.76 Million | ILA47.29 Million | -29.26pp |
| 2019-12-31 | 41.43% | ILA22.19 Million | ILA53.57 Million | -6.14pp |
| 2018-12-31 | 47.56% | ILA26.75 Million | ILA56.23 Million | -25.22pp |
| 2017-12-31 | 72.78% | ILA44.37 Million | ILA60.97 Million | -12.36pp |
| 2016-12-31 | 85.14% | ILA33.15 Million | ILA38.94 Million | +3.04pp |
| 2015-12-31 | 82.10% | ILA42.12 Million | ILA51.30 Million | +2.32pp |
| 2014-12-31 | 79.78% | ILA28.85 Million | ILA36.17 Million | +33.22pp |
| 2013-12-31 | 46.56% | ILA9.29 Million | ILA19.95 Million | +33.94pp |
| 2012-12-31 | 12.62% | ILA3.07 Million | ILA24.31 Million | -46.29pp |
| 2011-12-31 | 58.91% | ILA17.28 Million | ILA29.34 Million | +40.78pp |
| 2010-12-31 | 18.13% | ILA28.04 Million | ILA154.61 Million | -8.56pp |
| 2008-12-31 | 26.69% | ILA30.89 Million | ILA115.73 Million | +25.11pp |
| 2007-12-31 | 1.58% | ILA3.27 Million | ILA207.88 Million | -12.33pp |
| 2006-12-31 | 13.91% | ILA2.80 Million | ILA20.12 Million | -- |